Document text
Principal Investigator: Narges Alipanah-Lechner
Organization: UNIVERSITY OF CALIFORNIA, SAN FRANCISCO
Fiscal Year: 2024
Award: $46,244
Funding agency: National Heart Lung and Blood Institute
PROJECT SUMMARY/ABSTRACT
Acute Respiratory Distress Syndrome (ARDS), caused by a variety of triggers including COVID-19, is a
devastating critical illness without effective therapies. Despite numerous studies on COVID-19 related ARDS
(CARDS), the best available treatments lead to only modest or inconsistent clinical improvements. This paucity
of discoveries is likely in part due to heterogeneity of host response to COVID-19. The long-term goal is to bring
precision therapies to patients with ARDS and CARDS. Using plasma protein biomarkers and clinical data, Dr.
Calfee (sponsor of the applicant) has identified two biologic subphenotypes of non-COVID-19 related or “typical”
ARDS. Specifically, patients with the hyperinflammatory subphenotype had higher levels of inflammatory
biomarkers, metabolic acidosis, and shock. They also experienced significantly higher mortality and were more
likely to benefit from certain ICU therapies. Conversely, most CARDS patients demonstrate a hypoinflammatory
subphenotype of typical ARDS, raising questions about the pathophysiology underlying poor outcomes in this
population. The overall objective of this project is to (i) identify plasma biomarkers and differential gene
expression associated with poor outcomes in CARDS and (ii) search for the presence of CARDS specific
subphenotypes of clinical importance. The central hypothesis is that differential gene expression indicative of
dysregulated inflammation and high baseline plasma biomarkers of lung injury and disordered coagulation will
predict poor outcomes in CARDS, and that distinct CARDS subphenotypes exist associated with differential
outcomes and treatment responses. The rationale for this project is that it will offer mechanistic insights into the
biology underlying poor outcomes in this population, lead to identifying potential druggable targets, and identify
patients most likely to benefit from targeted therapies. The central hypothesis will be tested by pursuing these
specific aims: 1) Identify biological predictors of poor clinical outcomes within patients with CARDS; and 2)
Identify distinct biologic subphenotypes of CARDS associated with poor clinical outcomes and differential
treatment response. Under aim 1, hypothesis-driven plasma protein biomarkers will be measured, and RNA
sequencing performed on blood samples of CARDS patients enrolled in ISPY COVID, an ongoing adaptive
randomized controlled trial of experimental drugs across multiple US institutions. Under aim 2, latent class
analysis will be performed on a combination of protein biomarkers and clinical variables to identify
subphenotypes associated with distinct outcomes and responses to the trial’s investigational agents. The
proposed research is innovative, because extensive biological phenotyping in a large and representative cohort
of patients with a uniform trigger for ARDS has not been done and may be the key to identifying successful
therapies. Ultimately, this knowledge will pave the way for conducting phenotype-aware trials studying targeted
therapies in patients with subphenotypes of CARDS.
Terms: <ARDS><Acute Respiratory Distress><Acute Respiratory Distress Syndrome><Adult ARDS><Adult RDS><Adult Respiratory Distress Syndrome><Awareness><Biological><Biological Markers><Biology><Blood Coagulation Disorders><Blood Plasma><Blood Sample><Blood specimen><COVID associated ARDS><COVID associated acute respiratory distress syndrome><COVID crisis><COVID epidemic><COVID induced ARDS><COVID induced acute respiratory distress syndrome><COVID infected patient><COVID pandemic><COVID patient><COVID positive patient><COVID related ARDS><COVID related acute respiratory distress syndrome><COVID-19><COVID-19 associated ARDS><COVID-19 associated acute respiratory distress syndrome><COVID-19 crisis><COVID-19 epidemic><COVID-19 era><COVID-19 global health crisis><COVID-19 global pandemic><COVID-19 health crisis><COVID-19 induced ARDS><COVID-19 induced acute respiratory distress syndrome><COVID-19 infected patient><COVID-19 pandemic><COVID-19 patient><COVID-19 period><COVID-19 positive patient><COVID-19 public health crisis><COVID-19 related ARDS><COVID-19 related acute respiratory distress syndrome><COVID-19 years><COVID-19/ARDS><COVID-19/acute respiratory distress syndrome><COVID/ARDS><COVID/acute respiratory distress syndrome><COVID19 associated ARDS><COVID19 associated acute respiratory distress syndrome><COVID19 induced ARDS><COVID19 induced acute respiratory distress syndrome><COVID19 patient><COVID19 positive patient><COVID19 related ARDS><COVID19 related acute respiratory distress syndrome><COVID19/ARDS><COVID19/acute respiratory distress syndrome><CV-19><Cessation of life><Circulatory Collapse><Clinical><Clinical Data><Coagulation Disorder><Coagulopathy><Coronavirus Infectious Disease 2019><Critical Illness><Critically Ill><Da Nang Lung><Data><Data Analytics><Death><Diagnostic><Differential Gene Expression><Drugs><Dysfunction><Enrollment><Functional disorder><Future><Gene Expression><Goals><Health Care Systems><Healthcare Systems><Heterogeneity><Immune response><Immunological response><Inflammation><Inflammatory><Institution><Knowledge><Lead><Liquid substance><Lung Diseases><Lung damage><Measures><Medication><Mentorship><Metabolic acidosis><NHLBI><National Heart, Lung, and Blood Institute><Outcome><Patients><Pb element><Pharmaceutical Preparations><Phenotype><Physiopathology><Plasma><Plasma Proteins><Plasma Serum><Population><Precision therapeutics><Public Health><Pulmonary Diseases><Pulmonary Disorder><RNA Seq><RNA sequencing><RNAseq><Randomized, Controlled Trials><Research><Reticuloendothelial System, Serum, Plasma><Role><SARS-CoV-2 associated ARDS><SARS-CoV-2 associated acute respiratory distress syndrome><SARS-CoV-2 epidemic><SARS-CoV-2 global health crisis><SARS-CoV-2 global pandemic><SARS-CoV-2 induced ARDS><SARS-CoV-2 induced acute respiratory distress syndrome><SARS-CoV-2 infected patient><SARS-CoV-2 pandemic><SARS-CoV-2 patient><SARS-CoV-2 positive patient><SARS-CoV-2 related ARDS><SARS-CoV-2 related acute respiratory distress syndrome><SARS-CoV-2/ARDS><SARS-CoV-2/acute respiratory distress syndrome><SARS-coronavirus-2 epidemic><SARS-coronavirus-2 pandemic><Severe Acute Respiratory Syndrome CoV 2 epidemic><Severe Acute Respiratory Syndrome CoV 2 pandemic><Severe acute respiratory syndrome coronavirus 2 epidemic><Severe acute respiratory syndrome coronavirus 2 pandemic><Shock><Shock Lung><Simvastatin><Stiff lung><Strategic vision><Syndrome><Synvinolin><Testing><Therapeutic><Time><Tissue-Specific Differential Gene Expression><Tissue-Specific Gene Expression><Trachea><Trachea Proper><Training><United States><Whole Blood><Work><aspirate><bio-markers><biologic><biologic marker><biomarker><biomarker identification><bleeding disorder><circulatory shock><clotting disorder><cohort><coronavirus disease 2019><coronavirus disease 2019 associated ARDS><coronavirus disease 2019 associated acute respiratory distress syndrome><coronavirus disease 2019 crisis><coronavirus disease 2019 epidemic><coronavirus disease 2019 global health crisis><coronavirus disease 2019 global pandemic><coronavirus disease 2019 health crisis><coronavirus disease 2019 induced ARDS><coronavirus disease 2019 induced acute respiratory distress syndrome><coronavirus disease 2019 infected patient><coronavirus disease 2019 pandemic><coronavirus disease 2019 patient><coronavirus disease 2019 positive patient><coronavirus disease 2019 public health crisis><coronavirus disease 2019 related ARDS><coronavirus disease 2019 related acute respiratory distress syndrome><coronavirus disease 2019/ARDS><coronavirus disease 2019/acute respiratory distress syndrome><coronavirus disease associated ARDS><coronavirus disease associated acute respiratory distress syndrome><coronavirus disease crisis><coronavirus disease epidemic><coronavirus disease induced ARDS><coronavirus disease induced acute respiratory distress syndrome><coronavirus disease infected patient><coronavirus disease pandemic><coronavirus disease patient><coronavirus disease positive patient><coronavirus disease related ARDS><coronavirus disease related acute respiratory distress syndrome><coronavirus disease-19><coronavirus disease-19 global pandemic><coronavirus disease-19 pandemic><coronavirus disease-19 patient><coronavirus disease/ARDS><coronavirus disease/acute respiratory distress syndrome><coronavirus infectious disease-19><coronavirus patient><disease of the lung><disorder of the lung><drug/agent><druggable target><effective therapy><effective treatment><enroll><epithelial injury><experience><fluid><heavy metal Pb><heavy metal lead><high risk><host response><identification of biomarkers><identification of new biomarkers><immune system response><immunoresponse><improved><innovate><innovation><innovative><insight><interest><liquid><lung disorder><lung injury><marker identification><mortality><novel><participant enrollment><pathophysiology><patient enrollment><patient infected with COVID><patient infected with COVID-19><patient infected with SARS-CoV-2><patient infected with coronavirus disease><patient infected with coronavirus disease 2019><patient infected with severe acute respiratory syndrome coronavirus 2><patient with COVID><patient with COVID-19><patient with COVID19><patient with SARS-CoV-2><patient with coronavirus disease><patient with coronavirus disease 2019><patient with severe acute respiratory distress syndrome coronavirus 2><peripheral blood><precision medicine><precision therapies><precision treatment><precision-based medicine><predict clinical outcome><protein biomarkers><protein markers><pulmonary damage><pulmonary injury><pulmonary tissue damage><pulmonary tissue injury><randomized control trial><response><response to therapy><response to treatment><severe acute respiratory syndrome coronavirus 2 associated ARDS><severe acute respiratory syndrome coronavirus 2 associated acute respiratory distress syndrome><severe acute respiratory syndrome coronavirus 2 global health crisis><severe acute respiratory syndrome coronavirus 2 global pandemic><severe acute respiratory syndrome coronavirus 2 induced ARDS><severe acute respiratory syndrome coronavirus 2 induced acute respiratory distress syndrome><severe acute respiratory syndrome coronavirus 2 infected patient><severe acute respiratory syndrome coronavirus 2 patient><severe acute respiratory syndrome coronavirus 2 positive patient><severe acute respiratory syndrome coronavirus 2 related ARDS><severe acute respiratory syndrome coronavirus 2 related acute respiratory distress syndrome><severe acute respiratory syndrome coronavirus 2/ARDS><severe acute respiratory syndrome coronavirus 2/acute respiratory distress syndrome><shocks><skills><social role><targeted drug therapy><targeted drug treatments><targeted therapeutic><targeted therapeutic agents><targeted therapy><targeted treatment><therapeutic response><therapy response><transcriptome profiling><transcriptome sequencing><transcriptomic profiling><transcriptomic sequencing><transcriptomics><treatment effect><treatment response><treatment responsiveness><wet lung><windpipe>